Purchase this article with an account.
T-H Wang, P Hung; Comparison Between Chronic Angle-closure Glaucoma and Primary Open-angle Glaucoma for the Safety and Efficacy of Latanoprost After 2-year Follow Up . Invest. Ophthalmol. Vis. Sci. 2002;43(13):280.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:To investigate the long term safety and efficacy of latanoprost for chronic angle-closure glaucoma (CACG) and compare with that of primary open-angle glaucoma (POAG). Methods:The patients in both groups had the intraocular pressures (IOP) in the range of 20 to 35 mmHg after discontinuation of all antiglaucoma medications and the presence of glaucomatous optic neuropathy and/or visual filed defects. CACG was defined as the presence of more than 180 degree appositional closed anterior chamber angle and signs of peripheral anterior synechiae on Zeiss indentation gonioscopy. POAG was defined as a normal and open angle on gonioscopic examination. No previous ocular surgery or laser treatment was noted in all patients, except every CACG patient had received laser iridectomy. One drop of 0.005% latanoprost daily was the only treatment for every patient in the 24-month follow up period. Results:We enrolled 69 CACG patients (Male/Female: 17/52) with the age of 59.4¡Ó10.2 y/o, and 76 POAG patients (Male/Female: 42/34) with the age of 45.2¡Ó18.0 y/o. The baseline IOP was 24.3¡Ó3.4 mmHg in the CACG group and 23.9¡Ó2.7 in the POAG. After 2-year follow up, the IOP was reduced from the baseline by 6.6¡Ó1.2 mmHg (27.6¡Ó5.17%)(n=56) in the CACG group, and 6.1¡Ó1.3mmHg (25.9¡Ó4.2%)(n=64) in the POAG. At the end of the study, 63.8% of CACG and 59.2% of POAG had a reduction of IOP from the baseline for more than 20%. The percentage of patient withdrawn because of uncontrolled IOP after treatment was 18.8% in CACG and 15.8% in POAG. The IOP after 2-yr treatment was significantly reduced from the baseline (p<0.001 in both groups), however, there was no difference between CACG and POAG. Conclusion:0.005% latanoprost is an effective treatment for IOP reduction in both CACG and POAG patients.
This PDF is available to Subscribers Only